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There  is abundant  evidence of  the  type-specific nature  of the  antibodies  that  protect 
mice against  infection with the meningococcus.  Miller and  Castles  (1),  in describing the 
use of gastric mucin as an adjuvant for the production of experimental meningococcalinfection 
in mice, noted that monovalent antimeningococcal rabbit sera afforded to mice passive pro- 
tection against organisms of the homologous type only.  Rake (2) observed that the protective 
power of antimeningococcal horse sera against Type I  organisms was correlated with their 
content  of antibody  precipitable by a  polysaccharide  isolated from Type  I  meningococci. 
Little (3) found that the titer of Type I  protective antibody in antimeningococeal sera ran 
parallel to the agglutinative titer,  as  determined  by testing with encapsulated  organisms. 
Pittman, Branham,  and Sockrider (4) reported that the protective potency of antimeningo- 
coccal horse sera was correlated with their content of type-specific precipitins as measured 
by the formation of halos around colonies of meningococci cultivated upon solid media con- 
taining the immune serum.  Mermel and Rake (5) showed that the Type II protective anti- 
body in Type II antimeningococcal rabbit sera was identical with the antibody to the type- 
specific  polypeptide hapten  isolated by  them. 
The present report concerns  antibody absorption experiments,  which were 
shnilar to those of Menzel and Rake and which demonstrated that  the Type I 
protective antibody in four antimeningococcal horse sera corresponded almost 
entirely to one component of the polysaccharide preparations  (these  prepara- 
tions were designated "SI") previously isolated  from Type I meningococci  (6). 
Materials  and Methods 
The four sera employed in the present experiments were selected because of the diversity 
of their origins, which,  it was felt, would broaden  the significance  of the results.  Serum 
"A" was a sample of the fourth bleeding in the series of monovalent sera previously studied 
by the authors (7).  The bleeding date was February 1, 1934, and the serum contained 0.0l 
per cent merthiolate (Lilly).  Serum "B" was the polyvalent serum "B" discussed previously 
(8),  a  commercial preparation not acceptable for marketing because of a  deficiency of anti- 
bodies other than Type I.  It contained a phenolic preservative.  Serum "C" was a sample 
from a freshly prepared batch of polyvalent serum, from a different commercial source than 
'B."  Serum "D" was of considerable historical interest, since it was prepared at The Rocke- 
feller Institute for Medical Research in 1918, when an intensive effort was made to perfect 
antimeningococcal sera, especially for use by the armed, forces.  It had been stored mean- 
while in refrigerators without the addition of preservatives and still possessed  a  quite saris- 
factory content  of antibody  to SI. 
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The course of the reactions between SI and sera B, C, and D was analyzed by the quan- 
titative precipitation test in the fashion previously described (8).  The polysaccharide prep- 
arations used, Nos. 18 and 19, had been the subject'of previous chemical and immunological 
an~ays~ (8). 
P/0tection tests were carried out in the manner already described, the results being ex- 
pressed in provisional units (9).  Values for absorbed sera were corrected for dilution, so as 
to be directly comparable to those for the original,  undiluted sera. 
TABLE I 
Effect of Complete Absorption  with Type I  Meningococcal Polysacckaride Preparations  on the 
Type I  Protective TSter c ' Antimeningococcal  Horse Sera 
Serum  Protective titer  Protective anti-  body removed 
A Unabsorbed  ......................... 
A 'absbrbed i 
B Unabsbrbed  ......................... 
B k~sorbed. 
Cunab~sorbed  ......................... 
C absorbed.....'.... ......  i ........... 
Dunabsorbed..,...i..: ............... 
D  absorbed..'.!.~,..: .............. 
units per ml. 
50  50 
7  5 
420  420 
55  55 
740 
6 
100  100  104  125  110 






The double entries for sera A and B  represent the results of duplicate tests.  The data 
for  serum D  were taken from three separate experiments. 
RESULTS 
Effect of Removal of All Antibody Precipitable  by SI 
In. the fi~st group of experiments, the sera were treated with amounts  of 
SI, calculated from the data of quantitative precipitin analyses, to give maxi- 
mal precipitation of antibody and a  small, but definite excess of the polysac- 
eharide.  The reactions were carried out at 0°C. for 48 hours and the hapten- 
antibody precipitates were removed by centrifugation at from 4 to 6°C. 
The  results of protection  tests,  sumroafized in Table  I  showed that  the 
foregoing procedure removed from 87 to 99 per cent of the protective activity 
from the sera, and demonstrated, therefore, a  close correlation between pro- 
tective  antibody and  antibody to  the  polysaccharide preparation.  At  the 
time these experiments were done, it was not regarded as highly significant 
that the relatively small amount of from 5  to  13 per cent of the protective 
antibody was not precipitable from three of the sera.  It was thought that 
this residue might represent species-specific  antibody having protective power. 
On the other hand, the excellent results obtained with the  freshly prepared H. W.  SCHERP AND G. RAKE  87 
serum C  suggested that a  diminution of the precipitability  of the antibodies 
had occurred in the other three sera, which ranged  in age from approximately 
2  to 20 years.  Against this explanation, however, was  the fact that 95  per 
cent of the protective antibody was precipitable by SI from serum D, the oldest 
one tested. 
Kabat,  Miller,  Kaiser,  and  Foster  (10)  have reported recently that  only 
from 30 to 60 per cent of the protective antibody was precipitable from an 
antimeningococcal horse serum by various preparations  of SI,  including one 
of the authors'.  Absorption was even less complete in the case of two rabbit 
antisera and one chicken antiserum, and varied from 0  to 88 per cent in the 
case of four convalescent human sera.  The residual protective antibody was 
shown to be type-specific by appropriate absorptions with intact meningococci. 
In view of these results, it appears most likely that the unabsorbed protective 
antibody in  the present  experiments  corresponded to  this  new  type-specific 
antibody,  which  constituted,  however,  but  a  small  proportion  of  the  total 
antibody in the four sera studied. 
Effect of Selective Removal of Antibody by SI 
A quantitative study of the precipitation reaction between SI and polyvalent 
antimeningococcal horse sera (8) indicated that SI consisted of (a) a true type- 
specific substance,  "SSS,"  and  (b)  a  component which  was  designated  "X" 
because its nature was not then precisely defined, but which was most probably 
group-specific polysaccharide.  The proportion of SSS  to X  in the available 
preparations of SI was estimated to be 4:1, whereas the polyvalent sera con- 
tained the antibodies in approximately the inverse proportion. 
Fig.  1 depicts the" course of the reaction between SI No.  18 and serum C, 
which was typical of six sera tested (sera B, C, D, and three sera studied pre- 
viously (8)).  According to the interpretation given (8),  the first portion of 
the curve, described by the  equation, N  =  33.0  S -- 307  S  2, represents the 
combined reactions (SSS  +  anti-SSS) +  (X +  anti-X).  In the second por- 
tion of the curve,  described by the  equation, N  --- 0.30 +  17.0  S --  76.2 S  2, 
the precipitation of anti-SSS is complete and is represented by the constant 
(i.e., the anti-SSS content of the serum is 0.300 mg. of antibody N  per ml.). 
If the foregoing interpretation is correct and if protection of mice is afforded 
only by anti-SSS, then partial absorption of a serum at a point corresponding 
to A in Fig.  1 should be as effective as complete absorption in removing pro- 
tective antibody, even though a  considerable fraction of the  anti-X remains 
in the serum.  This expectation was realized in experiments with sera  C and 
D, the results of which are summarized in Table II, and strongly support  the 
conclusion that anti-X is devoid of protective action. 
Serum C.--The results of the quantitative precipitin analysis of this serum 
showed that it contained 0.30 mg. of anti-SSS nitrogen and 1.09 rag. of anti-X 88  M'ENINGOCOCCAL INFECTION.  XIII 
nitrogen per ml.  A sample of the serum was partially absorbed in the manner 
discussed above, so that it still contained 0.44 rag. of anti-X nitrogen per nil., 
which was 40 per cent of the amount originally present. 
Serum D.--The results of the quantitative precipitin analysis of this serum 
showed that it contained 0.27 rag. of anti-SSS nitrogen and 0.38 rag. of anti-X 
nitrogen per ml.  Selective absorption in the manner described left 0.28 rag. 
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FIo. 1. Typical precipitation reaction between a Type I  meningococcaJ polysaccharide 
preparation and  polyvaJent antimeningococcal horse serum.  Polysaccharide preparation 
SI No. 18 and 1 ml. portions of serum C. 
The foregoing results  were correlated with  the  agglutination  titers  of the 
respective sera.  In order to make the test as type-specific as possible, the test 
antigen consisted of a  suspension of unkilled organisms  taken from a  4 hour 
culture on blood agar of a virulent strain of Type I meningococcus.  The test 
mixtures were incubated for 2 hours at 37°C. and overnight in a  refrigerator 
(11).  The results,  also given in Table II,  showed good correlation between 
absorption of protective antibody and absorption of type-specific agglutinin. 
All of these results define an anomaly: the Type I, specific, protective anti- 
body of these antimeningococcal horse sera was but a  minor fraction of the 
total, berg secondary in amount to a group-specific, non-protective antibody 
which  corresponded to  a  minor  component of the preparations  of  polysac- 
charide separated by the authors from autolysates of Type I  meningococci. H. W.  SCI~ERP AND G. RAKE  89 
Kabat  et al.  (10)  have obtained similar results in experiments  of a  somewhat 
different nature,  and have shown in addition  that the same relationships pre- 
vail in the immunological response of human beings to Type I  meningococcal 
infection,  treated  with  sulfonamides.  These  findings  are  in  sharp  contrast 
to  the  usual  situation,  exemplified  by  antipneumococcal  sera  (12),  which  is 
dominated  by  the  formation  of  antibody  to  the  capsular  substance.  This 
antibody is also the principal protective  antibody. 
TABLE II 
Effect of Selective Absorption  wilk Type I  Meningococcal Polysaccharide Preparations on tke 
Type  I  Prolective Titer  of  Antimeningococcal  Horse  Sera 
Anti-SSS  Anti-X  Protective 
Serum  nitrogen  nitrogen  fiter 
units per ml. 
C unabsorbed ............................... 
C partially absorbed .......................... 
C completely absorbed ....................... 
D unabsorbed ............................... 
D partially absorbed ......................... 
D completely absorbed ....................... 
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Agglutination  Tests  with  the  Above Sera 
Dilution of serum 
C unabsorbed ............. 
C partially  absorbed ....... 
E completely absorbed ..... 
O unabsorbed ............. 
D partially absorbed ....... 
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It  seems  possible  that  this  peculiar  behavior  of Type  I  meningococcus is 
circumstantial,  depending more upon the amounts  of the respective  antigens 
present  at inununization  than upon differences in their antigenicity.  Type I 
meningococci  readily  undergo  dissociation  accompanied  by  loss  of  capsular 
antigen  (11),  they are easily decapsulated  by chemical treatment  (3),  and in 
cultures more than 5 hours old, they lose virulence (1), a property presumably 
associated  with  the presence of the  type-specific capsular antigen.  There is, 
therefore,  a  considerable  likelihood  that  a  vaccine  of  Type  I  meningococci 
may be faulty in its content of type-specific capsular antigen and be dominated 
by one of file somatic antigens,  the antibody to which would be expected  to 90  MIENINGOCOCCAL  INFECTION.  Xlll 
be of low protective value,  That this situation can be avoided is indicated by 
the  results  of  experiments  reported  previously.  The  present  authors  (7) 
studied eight sera withdrawn from a  horse over a  period of 2 years, during 
which the animal received repeated injections of young cultures of recently 
isolated strains of Type I  meningococcus.  Under these conditions, the anti- 
body response was almost exclusively type-specific. 
It was pointed out previously (8)  that there were considerable variations 
in the antigen-combining capacity of the anti-SSS  in different antimeningo- 
coccal horse sera, a phenomenon similar to that noted earlier by Goodner and 
Horsfall (13)  with antipneumococcal horse sera.  A  like variability was ob- 
served in the protective capacity of the antibody in the present experiments. 
The protective titers per nag. of anti-SSS  nitrogen were respectively: serum 
B, 1000; serum C, 2470; serum D, 400.  The data indicate, furthermore, that 
the protective titer may not be proportional to the antigen-combining capacity 
of the antibody.  The amounts of SI taken up per rag. of anti-SSS nitrogen, 
at the point of complete precipitation of anti-SSS  without excess  SSS,  were 
estimated to be respectively: serum B, 0.071 rag.; serum C, 0.130  rag.; serum 
D, 0.067 mg.  On this basis, sera B and D should have had the same protective 
titers per milligram of anti-SSS nitrogen, whereas the value for serum C should 
have been 1.9 times as great.  In view of the discrepancy between these pre- 
dictions and  the experimentally determined values, it becomes necessary to 
conclude that the protective titer of antimeningococcal horse sera cannot be 
estimated reliably by quantitative precipitin analysis. 
On the Protective Effect of A gar-Specific Antibody 
The sera of horses and rabbits, which have received injections of bacteria 
cultivated upon media solidified by agar, frequently contain an antibody which 
precipitates with agar, or with extracts and hydrolysates of agar (14).  Pre- 
sumably agar, or a hapten derived from it, is adsorbed by the bacteria, thereby 
acquiring antigenicity. 
Agar  antibody was present  in  each  of  six  therapeutic  antimeningococcal 
horse sera tested for it, the amounts ranging from 0.05 to 0.47 mg. of antibody 
nitrogen per ml.  It was absent from two samples of the monovalent anti- 
meningococcal sera prepared by the authors (7) and from a sample of commer- 
cially prepared meningococcal antitoxin. 
Because  of  the  widespread  occurrence  of  this  antibody and  because  the 
meningococci used  in  the  protection  test  are  customarily grown  on media 
solidified by agar, it seemed pertinent to ascertain if the antibody had any 
effect upon the results of the protection test.  To do this, the protective titers 
of sera A, B, and D  were determined before, and after, absorption with agar 
(Difco) or an agar hapten.  The latter was obtained in the course of an attempt 
to prepare group-specific meningococcal polysaccharide from Type II organ- H. W.  SCHERP AND G. RAKE  91 
isms  cultivated  on an agar-containing medium.  It failed  to react,  however, 
with any of the available antimeningococcal sere,  if these had been absorbed 
with  agar,  and  consequently  it  was  assumed  to have  only the  specificity  of 
agar.  It was used as a  test antigen for the absorption and quantitative  esti- 
mation  of agar-antibody in  the  present  experiments  because,  unlike  agar,  it 
did  not form precipitates  in normal  sere  and,  therefore,  should not have re- 
moved  antibody  or  other  serum  protein  in  an  immunologically  unspecific 
manner. 
TABLE III 
Effect  of Absorption  with Agar or Agar-Hapten oft  the  Type I  Protective Titer of 





















units per ml. 
50  50 
50  50 
420  420 
370  420 
100  100 
45  50 
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Experiment 2 




104  125 
87  104 
75  79 
Experiment 3 
units per nd. 
110 
92 
* This experiment was carried out over a year after the first one with serum B, which 
apparently underwent  some deterioration  in the interim.  Double entries in a single experi- 
ment are the results  of duplicate  tests. 
Since serum A  contained  no agar-antibody demonstrable  by the precipitin 
test,  it was expected that the absorption would have no effect upon the  pro- 
tective titer, and such was the result (Table III).  With one possible exception, 
there was likewise no effect in the case of serum B, which had the highest con- 
tent of agar-antibody of the sere tested.  With serum D, however, the  absorp- 
tions caused an average decrease of 30 per cent in the protective titer.  Because 
of the  variability  of the  results,  they  were  examined  statistically  and  were 
found to be acceptable,  since the difference between the means was 3.4  times 
its standard error. 
Antimeningococcal horse sere may be encountered,  therefore, from which a 
portion  of the  Type  I  protective  antibody  can  be  absorbed  by agar.  This 
might be interpreted to indicate a fortuitous relationship between the chemical 
structures  of agar and Type I  meningococcal polysaccharide similar to cross- 
reactions  previously  reported  (15).  Agglutination  tests,  carried  out  with 92  MENINGOCOCCAL  INIFECTION.  XIII 
serum D  simultaneously with those recorded in Table II, showed, however, no 
diminution in the Type I  specific antibody titer following absorption by agar. 
This result supports  an alternative explanation, namely, that in certain cir- 
cumstances agar-antibody protects mice against infection by Type I meningo- 
cocci,  presumably  acting  upon  the  agar  hapten  adsorbed  by  the  bacteria. 
Because serum D  is unique in this respect at present,  it does not seem per- 
missible to draw a definitive conclusion, except that agar antibody is a potential 
cause of variability in mouse protection tests. 
SIYMMARY 
Absorption  tests indicated that the protective antibody (Type I)  in four 
antimeningococcal horse sera corresponded closely to one of the components 
of the po]ysaccharide preparation previously isolated by the authors from Type 
I  meningococci.  This antibody was, however, a  minor fraction in the three 
therapeutic sera tested, being secondary in amount to non-protective antibody 
corresponding to another component of the polysaccharide preparation, plus 
antibody corresponding to agar.  In one case, removal of the agar-antibody 
diminished the protective titer by 30 per cent. 
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